The Technical Analyst
Amarin Corporation PLC [AMRN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Amarin Corporation PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.94% $0.872
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 356.41 mill |
| EPS: | -0.150 |
| P/E: | -5.81 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 408.82 mill |
| Avg Daily Volume: | 1.762 mill |
| RATING 2024-04-18 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.81 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.99x |
| Company: PE -5.81 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.191 (-121.85%) $-1.062 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.810 - 0.934 ( +/- 7.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-01 | Berg Aaron | Buy | 418 000 | Stock Option (right to buy) |
| 2024-02-01 | Berg Aaron | Buy | 116 000 | Restricted Stock Unit |
| 2024-02-01 | Reilly Thomas Charles | Buy | 418 000 | Stock Option (right to buy) |
| 2024-02-01 | Reilly Thomas Charles | Buy | 116 000 | Restricted Stock Unit |
| 2024-02-01 | Ketchum Steven B | Buy | 418 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 88.70 |
| Last 98 transactions |
| Buy: 14 626 335 | Sell: 697 874 |
Forecast:
16:00 - $0.881
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.881
Forecast 2: 16:00 - $0.881
Forecast 3: 16:00 - $0.881
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.872 (-4.94% ) |
| Volume | 1.020 mill |
| Avg. Vol. | 1.762 mill |
| % of Avg. Vol | 57.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AMRN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.235 | N/A | Active |
|---|
AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 08:00:00 - Press Release
Amarin To Report First Quarter 2024 Financial Results And Host Conference Call On May 1, 2024
Dublin, ireland and bridgewater, n.j., april 15, 2024 (globe newswire) -- amarin corporation plc (nasdaq:amrn) today announced that it will host a conference call with patrick holt, president & ceo, and members of amarin's senior management team to discuss its first quarter 2024 results followed by q&a on wednesday, may 1st, 2024, at 8:00 a.m. et.
2024-04-08 08:00:00 - Press Release
Amarin Highlights Key Data Providing Mechanistic Insights Into Eicosapentaenoic Acid (epa) At Acc.24
Data further advance understanding of vascepa®/vazkepa® potential mechanism of action data further advance understanding of vascepa®/vazkepa® potential mechanism of action
2024-04-06 15:30:00 - Press Release
New Reduce-it® Analyses Show Vascepa®/vazkepa® (icosapent Ethyl) Benefit In High-risk Cardiovascular Disease Patient Subgroups
-- findings presented on vascepa/vazkepa utility in reduce-it patient subgroups by baseline high/low lp(a), ldl-c levels -- -- lp(a) results published simultaneously in the journal of the american college of cardiology (jacc) –
2024-04-03 08:00:00 - Press Release
Amarin Provides Update On Vazkepa® (icosapent Ethyl) Intellectual Property Portfolio In Europe
Company's ip protection for vazkepa® in europe now extended into 2039 company's ip protection for vazkepa® in europe now extended into 2039
2024-03-25 08:00:00 - Press Release
Research Evaluating Benefits Of Vascepa®/vazkepa® (icosapent Ethyl) To Be Presented At The American College Of Cardiology's (acc) Annual Scientific Session & Expo
-- subgroup analyses from reduce-it ® and mechanistic data on icosapent ethyl(ipe)/eicosapentaenoic acid (epa) featured at the meeting -- dublin, ireland and bridgewater, n.j., march 25, 2024 (globe newswire) -- amarin corporation plc (nasdaq:amrn) today announced that additional patient subgroup analyses from the landmark reduce-it outcomes trial and mechanistic data on icosapent ethyl (ipe)/eicosapentaenoic acid (epa) will be presented at the american college of cardiology's annual scientific session & expo, april 6 – 8, 2024 in atlanta, ga.
Latest News
2024-04-15 08:00:00 - GlobeNewsWire
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET.
2024-04-04 14:21:04 - Zacks Investment Research
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
2024-04-03 16:13:08 - The Motley Fool
Why Amarin Stock Was Rocketing Higher on Wednesday
Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market.
2024-03-01 10:31:18 - Zacks Investment Research
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
2024-02-29 10:18:03 - Seeking Alpha
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript
2024-02-15 08:00:00 - GlobeNewsWire
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A.
2024-02-15 06:46:04 - Zacks Investment Research
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
2024-01-15 03:06:15 - Seeking Alpha
Amarin: Sarissa Is Giving Me Hope Again
Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future.
2024-01-12 11:19:20 - Zacks Investment Research
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
2024-01-11 11:20:13 - Zacks Investment Research
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million.